Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 35 Issue 3
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2017  >  35(3): 270-274

GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
Citation: GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
shu

Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review

doi: 10.3969/j.issn.1006-0111.2017.03.019

  • Division of Biological Therapies for Cancer, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China

  • Received Date: 2016-10-20
  • Rev Recd Date: 2017-03-07
  • Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence worldwide, especially in China. Surgical resection is the standard therapy for HCC. With the developments of surgical and supportive techniques, perioperative risk is significantly reduced, but the postoperative survival rate is low due to the high recurrence rate. In this article, we report a case with reoperation for recurrence after resection of primary hepatocellular carcinoma, and review the progress in prevention and treatment of recurrence after resection of primary HCC.
  • [1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
    [2] Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance[J]. Gastroenterology, 2004, 126(4): 1005-1014.
    [3] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.
    [4] Carr BI. Hepatocellular carcinoma: current management and future trends[J]. Gastroenterology, 2004, 127(5 Suppl 1): S218-224.
    [5] Gluer AM, Cocco N, Laurence JM, et al. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma[J]. HPB (Oxford), 2012, 14(5): 285-290.
    [6] Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation[J]. Hepatology, 1999, 30(6): 1434-1440.
    [7] Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(19): 1995-2004.
    [8] Sun HC, Tang ZY, Ma ZC, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background[J]. J Cancer Res Clin Oncol, 2005, 131(5): 284-288.
    [9] Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma[J]. Ann Surg, 2003, 238(5): 703-710.
    [10] Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors[J]. Ann Surg, 1999, 229(2): 216-222.
    [11] Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma[J]. Ann Surg Oncol, 2007, 14(8): 2337-2347.
    [12] Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes[J]. J Am Coll Surg, 2006, 202(2): 275-283.
    [13] Bellavance EC, Lumpkins KM, Mentha G, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?[J]. J Gastrointest Surg, 2008, 12(10): 1699-1708.
    [14] Li Q, Li H, Qin Y, et al. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience[J]. J Gastroenterol Hepatol, 2007, 22(11): 1936-1941.
    [15] Chong CC, Lee KF, Ip PC, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier?[J]. Surgeon, 2012, 10(5): 260-266.
    [16] Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group[J]. N Engl J Med, 1996, 334(24): 1561-1567.
    [17] Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet, 2000, 356(9232): 802-807.
    [18] Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 2003, 238(6): 885-893.
    [19] Yang W, Chen MH, Yin SS, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence[J]. AJR Am J Roentgenol, 2006, 186(5 Suppl): S275-283.
    [20] Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
    [21] Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5): 1164-1171.
    [22] Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015, 148(7): 1383-1391.
    [23] Hato T, Goyal L, Greten TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology, 2014, 60(5): 1776-1782.
    [24] Jiang G, Xu X, Ren S, et al. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma[J]. Tumour Biol, 2014, 35(4): 3405-3408.
    [25] Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J]. J Hepatol, 2014, 61(2): 309-317.
    [26] Hatzaras I, Bischof DA, Fahy B, et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(3): 758-766.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2890) PDF downloads(882) Cited by()

Related
Proportional views

Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review

doi: 10.3969/j.issn.1006-0111.2017.03.019
  • Division of Biological Therapies for Cancer, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
  • Received Date: 2016-10-20
  • Rev Recd Date: 2017-03-07

Abstract: Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence worldwide, especially in China. Surgical resection is the standard therapy for HCC. With the developments of surgical and supportive techniques, perioperative risk is significantly reduced, but the postoperative survival rate is low due to the high recurrence rate. In this article, we report a case with reoperation for recurrence after resection of primary hepatocellular carcinoma, and review the progress in prevention and treatment of recurrence after resection of primary HCC.

GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
Citation: GUO Lingling, DING Yongmei, ZHANG Qian. Reoperation for recurrence after resection of primary hepatocellular carcinoma: a case report and literature review[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 270-274. doi: 10.3969/j.issn.1006-0111.2017.03.019
shu

    HTML

Reference (26)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return